Compassionate use of orphan drugs

Compassionate use of orphan drugs

BACKGROUND EU regulation 726/2004 authorises manufacturers to provide drugs to patients on a temporary basis when marketing authorisation sought centrally for the entire EU is still pending. Individual Member States retain the right to approve and implement such 'compassionate use' programmes which companies will usually provide for free. Nevertheless some companies have opted not to partake in...

Use of Cytotoxic Drugs

استفاده روز افزون از داروهای سایتوتوکسیک باعث شده است که پرستاران بیشتر در معرض خطرات این مواد باشند. از این رو خانم جونیت گیبز ضمن مطالعه و بررسی در این زمینه راه هایی را جهت به حداقل رساندن این خطرات مطرح می کند.  

Orphan drugs revisited.

Commentary Orphan drugs revisited

C. MCCABE, A. TSUCHIYA, K. CLAXTON and J. RAFTERY From the Section of Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Department of Economics, University of Sheffield, Sheffield, Department of Economics and Related Studies, University of York, York, and Wessex Institute for Health Research and Development, University of Southampton, Southam...

Compassionate use of cell products

Investigational medicinal products are available to patients through two pathways. The first is by participating in a clinical trial, the second as part of a compassionate use program, which is the use of an investigational medicinal product outside a clinical trial in patients with serious or life-threatening diseases for which no other treatment is available or expected to be effective. Usual...